LURASIDONE

Lurasidone is an atypical antipsychotic blocking dopamine D2 and serotonin 5HT2A/5HT7 receptors, used for schizophrenia and bipolar depression. Side effects include akathisia, nausea, somnolence, weight gain, and metabolic changes. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

LURASIDONE displays a highdimensional biochemical interaction profile, integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential rebalancing, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer centres and polymeric scaffolding complexes, enabling wideband influence across metabolic, genomic, structural and electrophysiological layers.

At the signalling level, LURASIDONE may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3KAKT axes, modulate Gprotein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP/DAG cascade topology, and recalibrate cAMPPKA amplitude distributions. Mitochondrial effects can include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifts and bidirectional stresssignal integration between ER and mitochondrial compartments.

Advanced

  • Kinomescale catalyticcascade interference mapping
  • Highresolution docking & conformationaltransition simulations
  • UPR/ERstress, mitophagy & autophagicflux network analysis
  • Full multiomics integration (RNAseq, proteomics, phosphoproteomics, metabolomics)
  • Cytoskeletal mechanics & polymerturnover/forcedistribution modelling
  • Cellfate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AIdriven SAR/QSAR pipelines for compoundperformance prediction

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidantbuffer saturation
  • Mitochondrial fragmentation or ETCaxis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity loss
  • Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
  • Induction of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation imbalance

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C28H36N4O2S

Molecular Weight

492.7 g/mol

CAS Number

367514-87-2

Storage Condition

Conditions for safe storage, including any incompatibilities: Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Recommended storage temperature -20 °C

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Lurasidone; 367514-87-2; lurasidona; lurasidonum; SM-13496 FREE BASE

IUPAC/Chemical Name

(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

InChl Key

PQXKDMSYBGKCJA-CVTJIBDQSA-N

InChl Code

InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/213046;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download